
What is the sensitivity of SARS-CoV-2 RT-PCR done on…
For any questions or information, please email covidrapidreviewteam@gmail.com.
clinical specimen pediatric abridged>> Return to Rapid Reviews list.
For any questions or information, please email covidrapidreviewteam@gmail.com.
clinical specimen pediatric abridged>> Return to Rapid Reviews list.
For any questions or information, please email covidrapidreviewteam@gmail.com.
clinical outcomes pediatric Abridged>> Return to Rapid Reviews list.
The Unified COVID-19 Algorithms is an ongoing collaboration between volunteer facilitators, technical specialists and algorithm constructors, contributors and reviewers from different medical organizations, as well as students from the UP College of Medicine and Ateneo School of Medicine and Public Health. This release reflects evidence and policy updates, as well as medical community consensus since the call of the Health Professionals’ Alliance Against COVID-19 to restrategize the country’s response against COVID-19.
Each algorithm was reviewed by subject matter experts, stakeholders, as well as end- users. With the Philippine context in perspective, the algorithms provide clear guidelines for
COVID-19 management from both the community and hospital levels. Algorithms also reinforce recommendations of the Department of Health with emphasis on evidence-based decision making, as well as patient-centeredness.
Work on the first version of the Unified Algorithms was started as early as March 2020 with a small team of three volunteer facilitators, four algorithm constructors, and five core medical societies convened by the Asia-Pacific Center for Evidence-Based Healthcare and hosted by the Philippine Society for Microbiology and Infectious Diseases. With support from PSMID, this expansion was carried out by the HPAAC Steering Committee through its network of volunteers. These algorithms are subject to change as evidence emerges and guidelines are updated. Recommendations on patient care are not absolute. Final decisions remain under the discretion of the healthcare provider.
As the unified algorithms are utilized, end-users are enjoined to provide feedback as to their experience with use of the algorithms in the field through: secretariat@psmid.org and hpaac.org.ph/contact or secretariat@hpaac.org.ph.
The unified COVID-19 algorithms come in seven sections. Links to the different sections are provided below:
Section 4: Special Considerations
Section 5: Patient Reintegration
Dr. Marissa M. Alejandria
Dr. Romelei Camiling-Alfonso
Dr. Pauline F. Convocar
Dr. Antonio Miguel L. Dans
Dr. Anna Sofia Victoria S. Fajardo
Dr. Mario M. Panaligan
Dr. Aileen T. Riel-Espina
Dr. Maria Asuncion A. Silvestre
Philippine Society of Microbiology and Infectious Diseases
Philippine College of Physicians
Asia Pacific Center for Evidence Based Healthcare
Philippine Society of Public Health Physicians
Dr. Philippine Society of General Internal Medicine
Philippine College of Emergency Medicine
Philippine Society of Hospice and Palliative Medicine
Philpine College of Occupational Medicine
Kalusugan ng Mag-Ina
For any questions or information, please email: covidrapidreviewteam@gmail.com.
For any questions or information, please email: covidrapidreviewteam@gmail.com.
CP Abridged 29 Aug 2020 RGMFor any questions or information, please email: covidrapidreviewteam@gmail.com.
AsymptomaticPedia Abridged 04 Aug 2020 FCTFor any questions or information, please email covidrapidreviewteam@gmail.com.
ECLIA 20200823_180625For any questions or information, please email: covidrapidreviewteam@gmail.com.
RAgT_SR_22Aug2020_V4 FinalThis Interim Guidance on the Clinical Management of Adult Patients with Suspected or Confirmed COVID-19 Infection (Version 3.1) is an update of the March 31, 2020 guidelines released by the Philippine Society for Microbiology and Infectious Diseases. New evidence have been published since then necessitating this update.This document is written to guide clinicians and health care workers in their COVID-19 related management decisions. It is based on available scientific evidence that is also rapidly evolving, as more is discovered about the pathophysiology of SARS CoV-2 and the pathogenesis of the disease. As such, the recommendations in this guideline are based on limited, often low-quality evidence, and need to be carefully balanced with clinical judgment. The use of investigational drugs should be discussed with the patient or a legally authorized representative carefully outlining the potential adverse reactions and the potential clinical benefits of these investigational drugs. A signed informed consent should be obtained by the clinician.
DOWNLOAD the Interim Management Guidelines for COVID-19 (Version 3.1) here.